SXTP 60 DEGREES PHARMACEUTICALS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1946563 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.8%
TTM net income YoY-4.7%
TTM EPS YoY95.7%
Revenue 3-yr CAGR115.4%
Net income 3-yr CAGR—
Margins
Gross margin24.1%
Operating margin-971.9%
Net margin-921.0%
FCF margin-906.9%
EBITDA margin-964.6%
Returns
ROE-316.7%
ROA-170.7%
ROIC (approx.)-1,197.4%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets75.6%
Debt / equity0.18x
Current ratio1.17x
Interest coverage-1,207.18x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue12.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.01M | $607,574 |
| Cost of revenue | $781,695 | $384,765 |
| Gross profit | $223,776 | $222,809 |
| R&D expense | $2.11M | $4.99M |
| SG&A expense | $6.28M | $5.03M |
| Operating income | -$7.76M | -$9.72M |
| Interest expense | $7,805 | $7,912 |
| Pretax income | -$7.37M | -$7.96M |
| Income tax | $0 | $0 |
| Net income | -$7.37M | -$7.95M |
| EBITDA | -$7.72M | -$9.70M |
| EPS (basic) | -11.73 | -74.17 |
| EPS (diluted) | -11.73 | -74.17 |
| Weighted avg. shares (diluted) | 670,211 | 113,665 |
| Balance sheet | ||
| Cash & equivalents | $1.51M | $1.66M |
| Short-term investments | $1.24M | $1.73M |
| Receivables | $509,644 | $486,748 |
| Inventory | $656,924 | $442,764 |
| Current assets | $4.90M | $5.39M |
| PP&E, net | $246,365 | $149,808 |
| Intangibles | $224,361 | $157,084 |
| Total assets | $5.37M | $5.76M |
| Current liabilities | $1.85M | $1.66M |
| Short-term debt | $11,517 | $8,772 |
| Long-term debt | $144,003 | $147,119 |
| Total debt | $155,520 | $155,891 |
| Total liabilities | $1.99M | $1.80M |
| Shareholders' equity | $3.46M | $4.04M |
| Net debt | -$1.35M | -$1.50M |
| Shares outstanding | 1.16M | 141,749 |
| Cash flow statement | ||
| Operating cash flow | -$6.85M | -$5.65M |
| Capital expenditure | $139,881 | $103,773 |
| Free cash flow | -$6.99M | -$5.75M |
| Investing cash flow | $254,916 | -$1.89M |
| Financing cash flow | $6.44M | $7.05M |
| Depreciation & amortization | $43,324 | $11,726 |
| Stock-based compensation | $456,344 | $3.61M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.